NIH Auctions Off Taxpayer-Funded Gadgets for Licensing
Published Date: 9/16/2026
Notice
Summary
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-18937, Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form (Office of the Director/Office of Intramural Research)
The NIH Intramural Research Program (IRP) relies on a trustworthy research record to sustain public confidence and advance public health. NIH maintains procedures in compliance with NIH policy and 42 CFR part 93 to evaluate allegations of research misconduct, including falsification, fabrication, and plagiarism, through a fair, consistent, and peer-informed process. The proposed web-based reporting form will help the Agency Intramural Research Integrity Officer (AIRIO) receive sufficient information needed to assess concerns and determine appropriate next steps. Reports may be submitted anonymously, with optional contact information for follow-up. Concerns may also be reported in person, by telephone, or by email.
2026-18877, Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to MedGene Therapeutics, Inc. ("MedGene"), a company located in Silver Spring, Maryland, the United States of America.
2026-18646, Draft NIH Biosafety Policy for Research Involving Biohazards
The NIH is updating its biosafety rules to keep research safe as science changes and grows. This new policy will replace old guidelines and affect anyone working with biohazards in NIH-funded research. They want your thoughts by October 19, 2026, to help shape these important safety updates without adding extra costs.
2026-18191, Submission for OMB Review; 30-Day Comment Request Data and Specimen Hub (DASH) (Eunice Kennedy Shriver National Institute of Child Health and Human Development)
The National Institutes of Health (NIH) is asking for public feedback on their Data and Specimen Hub (DASH), which helps researchers share important health data. This is a quick 30-day review to make sure the information collection is clear and useful. If you’re involved in health research or data sharing, your input by October 8, 2026, can help shape how DASH works without costing extra money or time.
2026-17899, Proposed Collection; 60-Day Comment Request; Assurance (Interinstitutional, Foreign, and Domestic) and Annual Report (Office of the Director)
The NIH wants your thoughts on their plan to keep track of animal research safety through yearly reports and assurances from institutions, both in the U.S. and abroad. This helps make sure labs follow the rules and protect animals, with no new costs or big changes expected. You’ve got until October 2, 2026, to share your feedback and help improve the process!
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
Previous / Next Documents
Previous: 2026-18953, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in October 2026 to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants in brain, heart, blood, and cancer studies should note these dates as they impact funding decisions.
Next: 2026-18955, Notice of Open Meeting
In accordance with the requirements of the Federal Advisory Committee Act, the Millennium Challenge Corporation (MCC) Economic Advisory Council was established as a discretionary advisory committee on October 5, 2018. Its charter was most recently renewed on September 30, 2024, for two additional years. The MCC Economic Advisory Council serves MCC solely in an advisory capacity and provides advice and guidance to MCC economists, evaluators, leadership of the Department of Policy and Evaluation, and senior MCC leadership regarding relevant trends in development economics, applied economic and evaluation methods, poverty analytics, as well as modeling, measuring, and evaluating development interventions. In doing so, the MCC Economic Advisory Council helps sharpen MCC's analytical methods and capacity in support of the agency's mission. It also serves as a sounding board and reference group for assessing and advising on strategic policy innovations and methodological directions in MCC.